A systematic in vitro investigation on poly-arginine modified nanostructured lipid carrier: Pharmaceutical characteristics, cellular uptake, mechanisms and cytotoxicity

Asian Journal of Pharmaceutical Sciences

Volumn 12, Issue 1, 2017, Pages 51-58

  Sun, Mingshuang ^a   Gao, Yunyun ^a   Zhu, Zhihong ^a   Wang, Huixin ^a   Han, Cuiyan ^b   Yang, Xinggang ^a   Pan, Weisan ^a  

^a SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^b QIQIHAR MEDICAL UNIVERSITY   (China)

Author keywords

Cellular uptake; Cytotoxicity; Mechanisms; NLC; Poly arginine

Indexed keywords

ANTINEOPLASTIC AGENT; CAVEOLIN; CELL PENETRATING PEPTIDE; CLATHRIN; NANOCARRIER; POLYARGININE; POLYARGININE MODIFIED NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG;

A-549 CELL LINE; ARTICLE; CONFOCAL LASER SCANNING MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DISPERSITY; DRUG RELEASE; DRUG UPTAKE; ENDOCYTOSIS; FLOW CYTOMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; PARTICLE SIZE; PINOCYTOSIS; QUANTITATIVE ANALYSIS; SUSTAINED DRUG RELEASE; THERAPEUTIC INDEX; ZETA POTENTIAL;

EID: 84994527662     PISSN: 18180876     EISSN: 2221285X     Source Type: Journal    
DOI: 10.1016/j.ajps.2016.07.007     Document Type: Article

References (32)

1. [1] Perez-Herrero, E., Fernandez-Medarde, A., Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy. Eur J Pharm Biopharm 93 (2015), 52–79.
2. [2] Wang, X., Li, S., Shi, Y., et al. The development of site-specific drug delivery nanocarriers based on receptor mediation. J Control Release 193 (2014), 139–153.
3. [3] Danhier, F., Feron, O., Preat, V., To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148:2 (2010), 135–146.
4. [4] Mishra, P., Nayak, B., Dey, R.K., PEGylation in anti-cancer therapy: an overview. Asian J Pharm Sci 11:3 (2016), 337–348.
5. [5] Perillo, E., Allard-Vannier, E., Falanga, A., et al. Quantitative and qualitative effect of gH625 on the nanoliposome-mediated delivery of mitoxantrone anticancer drug to HeLa cells. Int J Pharm 488:1–2 (2015), 59–66.
6. [6] Arpicco, S., Lerda, C., Dalla Pozza, E., et al. Hyaluronic acid-coated liposomes for active targeting of gemcitabine. Eur J Pharm Biopharm 85:3 Pt A (2013), 373–380.
7. [7] Zhu, H., Liu, F., Guo, J., et al. Folate-modified chitosan micelles with enhanced tumor targeting evaluated by near infrared imaging system. Carbohydr Polym 86:3 (2011), 1118–1129.
8. [8] Kang, M.H., Park, M.J., Yoo, H.J., et al. RIPL peptide (IPLVVPLRRRRRRRRC)-conjugated liposomes for enhanced intracellular drug delivery to hepsin-expressing cancer cells. Eur J Pharm Biopharm 87:3 (2014), 489–499.
9. [9] Tang, J., Zhang, L., Liu, Y., et al. Synergistic targeted delivery of payload into tumor cells by dual-ligand liposomes co-modified with cholesterol anchored transferrin and TAT. Int J Pharm 454:1 (2013), 31–40.
10. [10] Zhang, W., Liu, J., Zhang, Q., et al. Enhanced cellular uptake and anti-proliferating effect of chitosan hydrochlorides modified genistein loaded NLC on human lens epithelial cells. Int J Pharm 471:1–2 (2014), 118–126.
11. [11] Hu, F.Q., Wu, X.L., Du, Y.Z., et al. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin. Eur J Pharm Biopharm 69:1 (2008), 117–125.
12. [12] Yuan, H., Miao, J., Du, Y.Z., et al. Cellular uptake of solid lipid nanoparticles and cytotoxicity of encapsulated paclitaxel in A549 cancer cells. Int J Pharm 348:1–2 (2008), 137–145.
13. [13] Shah, P.P., Desai, P.R., Channer, D., et al. Enhanced skin permeation using polyarginine modified nanostructured lipid carriers. J Control Release 161:3 (2012), 735–745.
14. [14] Chu, B., Qu, Y., Huang, Y., et al. PEG-derivatized octacosanol as micellar carrier for paclitaxel delivery. Int J Pharm 500:1–2 (2016), 345–359.
15. [15] Shen, Y., Chen, J., Liu, Q., et al. Effect of wheat germ agglutinin density on cellular uptake and toxicity of wheat germ agglutinin conjugated PEG-PLA nanoparticles in Calu-3 cells. Int J Pharm 413:1–2 (2011), 184–193.
16. [16] Telford, W.G., Near infrared lasers in flow cytometry. Methods 82 (2015), 12–20.
17. [17] Sahay, G., Alakhova, D.Y., Kabanov, A.V., Endocytosis of nanomedicines. J Control Release 145:3 (2010), 182–195.
18. [18] Biswas, S., Dodwadkar, N.S., Deshpande, P.P., et al. Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. Eur J Pharm Biopharm 84:3 (2013), 517–525.
19. [19] Torchilin, V.P., Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:4–5 (2008), 548–558.
20. [20] Vives, E., Schmidt, J., Pelegrin, A., Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 1786:2 (2008), 126–138.
21. [21] Zhang, T., Xue, X., He, D., et al. A prostate cancer-targeted polyarginine-disulfide linked PEI nanocarrier for delivery of microRNA. Cancer Lett 365:2 (2015), 156–165.
22. [22] Zhang, C., Tang, N., Liu, X., et al. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release 112:2 (2006), 229–239.
23. [23] Khalil, I.A., Kogure, K., Futaki, S., et al. High density of octaarginine stimulates macropinocytosis leading to efficient intracellular trafficking for gene expression. J Biol Chem 281:6 (2006), 3544–3551.
24. [24] Kim, H.K., Davaa, E., Myung, C.S., et al. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Int J Pharm 392:1–2 (2010), 141–147.
25. [25] Meade, B.R., Dowdy, S.F., Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 59:2–3 (2007), 134–140.
26. [26] Ramsey, J.D., Flynn, N.H., Cell-penetrating peptides transport therapeutics into cells. Pharmacol Ther 154 (2015), 78–86.
27. [27] Raucher, D., Ryu, J.S., Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol Med 21:9 (2015), 560–570.
28. [28] Oyarzun-Ampuero, F.A., Goycoolea, F.M., Torres, D., et al. A new drug nanocarrier consisting of polyarginine and hyaluronic acid. Eur J Pharm Biopharm 79:1 (2011), 54–57.
29. [29] Park, K., Arginine-rich CPPs for improved drug delivery to tumors. J Control Release, 159(2), 2012, 153.
30. [30] Zhao, Y., Ren, W., Zhong, T., et al. Tumor-specific pH-responsive peptide-modified pH-sensitive liposomes containing doxorubicin for enhancing glioma targeting and anti-tumor activity. J Control Release 222 (2015), 56–66.
31. [31] Futaki, S., Membrane-permeable arginine-rich peptides and the translocation mechanisms. Adv Drug Deliv Rev 57:4 (2005), 547–558.
32. [32] Khalil, I.A., Kogure, K., Futaki, S., et al. Octaarginine-modified liposomes: enhanced cellular uptake and controlled intracellular trafficking. Int J Pharm 354:1–2 (2008), 39–48.